Señales en vivo de 299660.KQ | Maximiza tus Ganancias con Getagraph.com

Live Chart Being Loaded With Signals

Commentary (1 jul 2024 @ 01:58):
Our systems believe the stock currently is undervalued by 0.03% compare to its pairs and should correct upwards.

Stats
Volumen de hoy	65 422
Volumen promedio	112 591
Capitalización de mercado	42.42B
EPS	KRW-241.94 ( Q1 \| 2024-03-31 )
Last Dividend	KRW0 ( N/A )
Next Dividend	KRW0 ( N/A )
P/E	0 (Sector) 0 (Industry) 0
ATR14	KRW5.65 (0.28%)

Correlación (AI algo v.1.1b): Undervalued: 0.03% KRW2 010.58 paired level. (El Algoritmo Rastrea Los Cambios De Las Acciones Más Correlacionadas En Tiempo Real Y Proporciona Una Actualización Instantánea)

Volumen Correlación

Largo: -0.02 (neutral)

Corto: 0.61 (weak)

Signal:(51.385) Neutral

Cellid, Co., Ltd. Correlación

10 Correlaciones Más Positivas

10 Correlaciones Más Negativas

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Cellid, Co., Ltd. Correlación - Moneda/Commodity

-0.13
( neutral )

-0.47
( neutral )

0.31
( neutral )

-0.19
( neutral )

0.39
( neutral )

0.47
( neutral )

Cellid, Co., Ltd. Finanzas

Annual	2023
Ingresos:	KRW0
Beneficio Bruto:	KRW-2.66B (0.00 %)
EPS:	KRW-1 078.05

FY	2023
Ingresos:	KRW0
Beneficio Bruto:	KRW-2.66B (0.00 %)
EPS:	KRW-1 078.05

FY	2022
Ingresos:	KRW480.00M
Beneficio Bruto:	KRW-2.38B (-495.54 %)
EPS:	KRW-2 141.24

Financial Reports:

No articles found.

Cellid, Co., Ltd. Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Cellid, Co., Ltd.

Cellid, Inc. develops immunothetherapeutic vaccines for cancer and/or infectious diseases therapies. It is developing BVAC-C for cervical, head and neck, anal, and genital cancer with human papilloma virus antigen; BVAC-B for gastric, ovarian, lung, and pancreatic cancer with HER-2/neu antigen; and BVAC-P for prostate, urinary tract, and brain cancer with PAP/PSMA antigens. The company is also developing BVAC-M for cancers, such as melanoma with GP100/MAGE-A3 antigens; and BVAC-Neo, a customized immunotherapeutic vaccine. Cellid, Inc. was founded in 2006 and is based in Seoul, South Korea.